Newest ulcer drug from AstraZeneca has a slight edge
Article Abstract:
AstraZeneca's new ulcer treatment drug, called Nexium, has proven itself to be slightly more effective than Losec, the preparation AstraZeneca produced for ulcer treatment previously. AstraZeneca goes through financial turmoil, and it has high hopes for the new medication.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Shares of Glaxo and SmithKline Slip Despite Upbeat Corporate News
Article Abstract:
Although both United Kingdom-based pharmaceuticals giants SmithKline Beecham PLC and Glaxo Wellcome PLC reported improved earnings, both companies' shares prices dropped.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Zeneca shareholders to decide Astra deal; few bars remain to creating No. 3 drug firm
Article Abstract:
Shareholders of United Kingdom's pharmaceuticals company Zeneca Group PLC meet to approve merger with Sweden's pharmaceuticals giant Astra AB. If approved by both companies' shareholders, the $35 billion merger will produce the third largest pharmaceuticals company in the world.
Comment:
Shareholders of Sweden's Astra AB and U.K.'s Zeneca Group PLC consider merger of both companies.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Vivendi aims to change statutes of company to curb voting rights. Vivendi plans to list shares in New York
- Abstracts: AstraZeneca shares decline 7.5% despite solid results, rosy outlook. AstraZeneca shares fall 2.5% after cutting sales outlook
- Abstracts: Lazard's shares drop in debut as private control ends at firm. Slow-going Eurobond session absorbs two debut offerings
- Abstracts: Pearson to acquire NCS for $2.5 billion; Move will create world's top education firm. Pearson buys Dorling Kindersley
- Abstracts: Fenosa is given the green light to take over rival Cantabrico. Shareholders reject Fenosa's offer to buy Cantabrico